Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes - Wikidata - awgldk - TriplyDB

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

http://www.wikidata.org/entity/Q28221962

about

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest Guidelines for the management of myeloproliferative neoplasms Clinical potential of pacritinib in the treatment of myelofibrosis A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis Gfi1b controls integrin signaling-dependent cytoskeleton dynamics and organization in megakaryocytes.Quantification of fibrosis and osteosclerosis in myeloproliferative neoplasms: a computer-assisted image study.The JAK2 exon 12 mutations: a comprehensive review.Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis Pharmacological management of essential thrombocythemia.Estimation of bone marrow cellularity using digital image nucleated cell counts in patients receiving chemotherapy.How I treat essential thrombocythemia.Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis Emerging treatments for essential thrombocythemia WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience.European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5--comment.European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.Quantification of IGF-1 Receptor May Be Useful in Diagnosing Polycythemia Vera-Suggestion to Be Added to Be One of the Minor Criterion Myeloproliferative Neoplasms in Children Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia.Genetic-pathologic characterization of myeloproliferative neoplasms.Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.Anagrelide: 20 years later.Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis.Experimental therapeutics for patients with myeloproliferative neoplasias.How to manage essential thrombocythemia.A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia.Myelofibrosis: an update on current pharmacotherapy and future directions.WHO classification of myeloproliferative neoplasms (MPN): A critical update.Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.Advances and challenges in the management of essential thrombocythemia.How we diagnose and treat essential thrombocythaemia.Myeloproliferative neoplasms: Morphology and clinical practice.Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.

P2860

Q24631288-96905639-4628-4883-AF24-A4F06AD56DCD Q26777398-E9D0C1B2-4BA4-4445-9DA7-C46B076DDE1B Q26778326-3B8834F0-CE21-4970-916F-775FE66CFF57 Q26796450-A79C0F52-7219-4785-8ED5-FCBF918AAEAF Q28553797-6923AF63-E2FC-48D7-AF66-91B815C25846 Q33438370-67629C83-CA06-4C90-8AD1-232DB12D8C6E Q33872534-EAA385D7-07D5-4547-8FEE-699FC60A6E88 Q34192739-0E0F9637-5582-48D1-892F-02A9A8E08AAB Q34247430-FCF860F1-BAF2-4726-B55F-1BF6A4F45AA3 Q34344384-44C60141-E8BB-498F-A944-DE8F1230BCC0 Q35115527-C9D07D93-4075-4CCD-AB00-222A619D3E23 Q35132271-92C263FC-076E-487B-B45F-6FA242C38EEA Q35532006-A4EE20F5-18E1-4DC5-8E79-A1D69428F572 Q35683853-5255C261-F28B-42BE-B0BB-66640493BCC4 Q35705470-92A28E52-39F4-406B-94FD-2C533D8A519B Q35794393-8E6BBE55-B011-4EC7-B794-CAF437DBF180 Q35794415-9F474D8E-34D2-459A-B6EE-787ACA2FC586 Q36182119-19062913-F249-43A4-9193-B04DFAFE1900 Q36305041-14FFFB9E-33FF-46AB-912E-4E872E295299 Q36316145-212355B9-FFEC-4EFB-A299-4492E96279AD Q36666769-E24C5FC0-540B-4417-9DA3-54B570BFAAC1 Q36874807-F84F4F26-8A95-4F6C-A483-B68F1974D459 Q36983755-9E063D93-85CB-44A9-9BBE-3705C1B04BD7 Q37151437-90191A58-B6CB-459E-AA0E-FF6D8E078078 Q37163590-04139650-2EAB-4B29-8E38-5959609AD79C Q37357291-AD405537-DBCD-44D1-AD5C-6D7ADF461CEA Q37575948-B45A1BB5-A749-46DE-9615-C3F4879028ED Q37797983-91128AF1-7B49-4FA1-8F63-0BB43213589A Q37952488-E0267608-E38A-4178-B3DC-9E77D92AA302 Q37955231-23C5D6AE-A316-4708-B4DA-784FCB1D8ED2 Q38014534-3A633632-F11B-4E9D-BCC9-A25EBEBC49AD Q38087202-18A634A3-AE9E-4215-B4EF-C6528443EE13 Q38091447-7BB128DB-41BE-40B3-AA80-69A4E5C3021C Q38154519-5AA1EDE7-72DB-443C-B188-56DA24A58148 Q38187675-7B25DD49-36A0-4C11-8075-94CB260A75EC Q38542093-0F5A8160-CE77-4402-A590-BBB74D42176A Q38606595-00400931-4A02-4F34-BDF1-FC99BCB0071D Q38683559-788D235C-E77F-435A-A966-5EB93BC79A11 Q38764516-B5EB8DFF-0636-4637-BAFC-D9C9707E72A3 Q38816384-12A7F426-F7C1-4944-947E-76C7767815B0

P2860

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

http://www.wikidata.org/entity/Q28221962

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Bone marrow pathology in essen ...... r identifying disease subtypes

@ast

Bone marrow pathology in essen ...... r identifying disease subtypes

@en

Bone marrow pathology in essen ...... r identifying disease subtypes

@nl

type

label

Bone marrow pathology in essen ...... r identifying disease subtypes

@ast

Bone marrow pathology in essen ...... r identifying disease subtypes

@en

Bone marrow pathology in essen ...... r identifying disease subtypes

@nl

prefLabel

Bone marrow pathology in essen ...... r identifying disease subtypes

@ast

Bone marrow pathology in essen ...... r identifying disease subtypes

@en

Bone marrow pathology in essen ...... r identifying disease subtypes

@nl

P1433

Q28221962-7C426D22-E1EA-4732-B092-AC5B16DB6BB7

P1476

Q28221962-2EB9BCBF-1D14-454A-92B5-3CB2CA05E81A

P2093

Q28221962-492BB199-35D3-4B6B-8B20-B7E23E6D258A

Q28221962-5B904900-FAA5-4C1C-9C10-B04D891B5081

Q28221962-82F02019-5E14-4084-85EA-92C8F62C623B

Q28221962-A43E76D8-032F-4F6B-BE71-9A3FA8EAF39B

Q28221962-B5DD2F2D-D4B5-4D8F-B53F-5A68CB352244

Q28221962-D7DB3010-5CF0-4887-88DC-F07AD22F06CF

Q28221962-E81FB8C4-6CAD-4EE8-AF84-8B1EAA5593F9

Q28221962-EF9B2308-B1C4-4A83-BE05-318850BC801C

P304

Q28221962-A1BDB25B-CA10-4C9D-9759-F50C4C837F00

P31

Q28221962-53E88E79-67DE-4DCC-B33C-BCD80C287E9B

P3181

Q28221962-D099FBEC-61FE-4C90-820E-7C56DF1A8C30

P356

Q28221962-AEA85A98-8690-4C57-B24C-D1CBAC7ABEEB

P407

Q28221962-BC8C134A-0290-47C9-8674-4EECB6C19F4B

P433

Q28221962-FC08D2D5-E667-4F34-94B4-7F31733841FC

P478

Q28221962-E18C6FDD-0BEE-4446-A398-03D01769CEDC

P50

Q28221962-03820016-D60A-47CC-BDEA-DA39C058C013

Q28221962-8FB26650-1FB9-4B13-8E66-E5DD9500568E

P577

Q28221962-EFAB7F95-705D-4B3E-B782-1D8EEEF2EEEB

P5875

Q28221962-A28D9B7E-77DA-4465-A77A-157E52A1FCC6

P698

Q28221962-C2073E4A-C362-4602-8688-81195C38EAC2

P921

Q28221962-346F3CCA-34C1-4DCB-AC43-D37BA3BFE973

Q28221962-3a4f32c1-4ae5-4229-a606-51cf54fdf8ef

P3181

P356

BLOOD-2007-05-091850

P1433

P1476

Bone marrow pathology in essen ...... r identifying disease subtypes

@en

P2093

Beverley Paul

http://www.w3.org/2001/XMLSchema#string

Bridget S Wilkins

http://www.w3.org/2001/XMLSchema#string

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

Clare L East

http://www.w3.org/2001/XMLSchema#string

David Bareford

http://www.w3.org/2001/XMLSchema#string

Keith Wheatley

http://www.w3.org/2001/XMLSchema#string

Peter J Campbell

http://www.w3.org/2001/XMLSchema#string

Wendy N Erber

http://www.w3.org/2001/XMLSchema#string

P304

60-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2687188

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2007-05-091850

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Anthony R Green

P577

2007-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5958334

http://www.w3.org/2001/XMLSchema#string

P698

17885079

http://www.w3.org/2001/XMLSchema#string

P921